Prof.A.Górski, MD, PhD is head of the Bacteriophage Laboratory and Phage Therapy Center.Hismain interests are phage therapy and immunobiology of phage. In the 2000s he presented a hypothesis on protective action of endogenous phages which involves not only their antibacterial but also antiinflammatory and immunomodulatory action. Subsequently, he formulated a hypothesis on phage translocation from the gastrointestinal tract to other tissues where phages could mediate their effects. In the past few years he has published articles envisaging the potential role of phages in the treatment of autoimmune disorders, allergy and graft-versus-host disease (“phage repurposing”)(A.Górski et al., Med Res Rev 2019 doi: 10.1002/med.21593). He was a co-editor of a book on phage therapy (see above).RyszardMiędzybrodzki MD, PhD has been engaged in preclinical studies on bacteriophage application in the treatment of bacterial infections as well as experimental phage therapy.Since 2013 he has also worked at the Department of Clinical Immunology, Medical University of Warsaw. He has published over 70 papers and five book chapters related to therapeutic phage application including new perspectives of clinical use of bacteriophages (anti-inflammatory and immunomodulating phage effects). He was a co-editor of the book Phage Therapy. Current Research and Applications published in 2014 by Caister Academic Press.Jan Borysowski MD, PhD works at the Department of Clinical Immunology, Medical University of Warsaw. His interests include phage therapy and medical ethics, especially ethical aspects of compassionate use. He has published over 40 papers and seven book chapters. His papers have been published, among others, by BMC Medicine, Frontiers in Immunology and Frontiers in Microbiology. Moreover, he was the lead editor of the book Phage Therapy. Current Research and Applications published in 2014 by Caister Academic Press.

• Part I: Bacteriophages as antibacterialagents.- Chapter 1:Production of PhageTherapeutics and Formulations – InnovativeApproaches.- Chapter 2:Phagepharmacokinetics: relationship with administrationroute.- Chapter 3:BacterialResistance to Phage and itsImpact on Clinical Therapy.- Part II:  Bacteriophages and the immune system.- Chapter 4:Phageinteraction with the mammalianimmune system.- Chapter 5:Humoralimmuneresponse to phage-basedtherapeutics.- Part III:Use of bacteriophages to combat bacterial infections.- Chapter 6:How to achieve a goodphage therapy clinical trial?.- Chapter 7: Perspectives on the RenewedInterest in the United States.- Chapter 8:Phage Therapy in Orthopaedic Implant-associated Infections.- Chapter 9:The use of bacteriophages in animalhealth and food protection.- Chapter 10:Combiningbacteriophages with otherantibacterialagents to combatbacteria.- Chapter 11: Phage therapy of infectious biofilms: Challenges and strategies.- Part IV:Phage therapy – regulatory and ethical aspects.- Chapter 12:Regulatory Considerations for Bacteriophage Therapy Products.- Chapter 13:Developing phagesintomedicines for Europe.- Chapter 14: Phagetherapy in Europe: Regulatory and intellectualpropertyprotectionissues.- Chapter 15:Ethics of phagetherapy.- Part V: Bacteriophage-derived antibacterial agents.- Chapter 16: NovelAlternative to Antibiotics.

Prof.A.Górski, MD, PhD is head of the Bacteriophage Laboratory and Phage Therapy Center.Hismain interests are phage therapy and immunobiology of phage. In the 2000s he presented a hypothesis on protective action of endogenous phages which involves not only their antibacterial but also antiinflammatory and immunomodulatory action. Subsequently, he formulated a hypothesis on phage translocation from the gastrointestinal tract to other tissues where phages could mediate their effects. In the past few years he has published articles envisaging the potential role of phages in the treatment of autoimmune disorders, allergy and graft-versus-host disease (“phage repurposing”)(A.Górski et al., Med Res Rev 2019 doi: 10.1002/med.21593). He was a co-editor of a book on phage therapy (see above).RyszardMiędzybrodzki MD, PhD has been engaged in preclinical studies on bacteriophage application in the treatment of bacterial infections as well as experimental phage therapy.Since 2013 he has also worked at the Department of Clinical Immunology, Medical University of Warsaw. He has published over 70 papers and five book chapters related to therapeutic phage application including new perspectives of clinical use of bacteriophages (anti-inflammatory and immunomodulating phage effects). He was a co-editor of the book Phage Therapy. Current Research and Applications published in 2014 by Caister Academic Press.Jan Borysowski MD, PhD works at the Department of Clinical Immunology, Medical University of Warsaw. His interests include phage therapy and medical ethics, especially ethical aspects of compassionate use. He has published over 40 papers and seven book chapters. His papers have been published, among others, by BMC Medicine, Frontiers in Immunology and Frontiers in Microbiology. Moreover, he was the lead editor of the book Phage Therapy. Current Research and Applications published in 2014 by Caister Academic Press.

• Part I: Bacteriophages as antibacterialagents.- Chapter 1:Production of PhageTherapeutics and Formulations – InnovativeApproaches.- Chapter 2:Phagepharmacokinetics: relationship with administrationroute.- Chapter 3:BacterialResistance to Phage and itsImpact on Clinical Therapy.- Part II:  Bacteriophages and the immune system.- Chapter 4:Phageinteraction with the mammalianimmune system.- Chapter 5:Humoralimmuneresponse to phage-basedtherapeutics.- Part III:Use of bacteriophages to combat bacterial infections.- Chapter 6:How to achieve a goodphage therapy clinical trial?.- Chapter 7: Perspectives on the RenewedInterest in the United States.- Chapter 8:Phage Therapy in Orthopaedic Implant-associated Infections.- Chapter 9:The use of bacteriophages in animalhealth and food protection.- Chapter 10:Combiningbacteriophages with otherantibacterialagents to combatbacteria.- Chapter 11: Phage therapy of infectious biofilms: Challenges and strategies.- Part IV:Phage therapy – regulatory and ethical aspects.- Chapter 12:Regulatory Considerations for Bacteriophage Therapy Products.- Chapter 13:Developing phagesintomedicines for Europe.- Chapter 14: Phagetherapy in Europe: Regulatory and intellectualpropertyprotectionissues.- Chapter 15:Ethics of phagetherapy.- Part V: Bacteriophage-derived antibacterial agents.- Chapter 16: NovelAlternative to Antibiotics.

Prof.A.Górski, MD, PhD is head of the Bacteriophage Laboratory and Phage Therapy Center.Hismain interests are phage therapy and immunobiology of phage. In the 2000s he presented a hypothesis on protective action of endogenous phages which involves not only their antibacterial but also antiinflammatory and immunomodulatory action. Subsequently, he formulated a hypothesis on phage translocation from the gastrointestinal tract to other tissues where phages could mediate their effects. In the past few years he has published articles envisaging the potential role of phages in the treatment of autoimmune disorders, allergy and graft-versus-host disease (“phage repurposing”)(A.Górski et al., Med Res Rev 2019 doi: 10.1002/med.21593). He was a co-editor of a book on phage therapy (see above).RyszardMiędzybrodzki MD, PhD has been engaged in preclinical studies on bacteriophage application in the treatment of bacterial infections as well as experimental phage therapy.Since 2013 he has also worked at the Department of Clinical Immunology, Medical University of Warsaw. He has published over 70 papers and five book chapters related to therapeutic phage application including new perspectives of clinical use of bacteriophages (anti-inflammatory and immunomodulating phage effects). He was a co-editor of the book Phage Therapy. Current Research and Applications published in 2014 by Caister Academic Press.Jan Borysowski MD, PhD works at the Department of Clinical Immunology, Medical University of Warsaw. His interests include phage therapy and medical ethics, especially ethical aspects of compassionate use. He has published over 40 papers and seven book chapters. His papers have been published, among others, by BMC Medicine, Frontiers in Immunology and Frontiers in Microbiology. Moreover, he was the lead editor of the book Phage Therapy. Current Research and Applications published in 2014 by Caister Academic Press.

• Part I: Bacteriophages as antibacterialagents.- Chapter 1:Production of PhageTherapeutics and Formulations – InnovativeApproaches.- Chapter 2:Phagepharmacokinetics: relationship with administrationroute.- Chapter 3:BacterialResistance to Phage and itsImpact on Clinical Therapy.- Part II:  Bacteriophages and the immune system.- Chapter 4:Phageinteraction with the mammalianimmune system.- Chapter 5:Humoralimmuneresponse to phage-basedtherapeutics.- Part III:Use of bacteriophages to combat bacterial infections.- Chapter 6:How to achieve a goodphage therapy clinical trial?.- Chapter 7: Perspectives on the RenewedInterest in the United States.- Chapter 8:Phage Therapy in Orthopaedic Implant-associated Infections.- Chapter 9:The use of bacteriophages in animalhealth and food protection.- Chapter 10:Combiningbacteriophages with otherantibacterialagents to combatbacteria.- Chapter 11: Phage therapy of infectious biofilms: Challenges and strategies.- Part IV:Phage therapy – regulatory and ethical aspects.- Chapter 12:Regulatory Considerations for Bacteriophage Therapy Products.- Chapter 13:Developing phagesintomedicines for Europe.- Chapter 14: Phagetherapy in Europe: Regulatory and intellectualpropertyprotectionissues.- Chapter 15:Ethics of phagetherapy.- Part V: Bacteriophage-derived antibacterial agents.- Chapter 16: NovelAlternative to Antibiotics.